• Coeptis Therapeutics Holdings posted a net loss of USD 4.02 million for the three months ended March 31, 2026, while revenue rose 80.92% to USD 113,771.
• Operating expenses edged down 2.24% to USD 3.98 million, while interest expense narrowed to USD 5,257 from USD 71,491 a year earlier.
• Unrealized loss on marketable securities was USD 176,045, while realized gain on sales of marketable securities totaled USD 85,407.
• Cash slipped to USD 5.21 million at quarter-end from USD 5.67 million at Dec. 31, 2025; cash used in operations was USD 1.76 million.
• After quarter-end, Coeptis completed a merger with Z Squared, issued 43,877,497 shares to former Z Squared stockholders, spun out most biopharmaceutical operations, changed its name to Z Squared, and began trading on Nasdaq under ticker ZSQR.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coeptis Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-003948), on May 15, 2026, and is solely responsible for the information contained therein.